Varex Imaging Corporation has announced its unaudited financial results for the second quarter of fiscal year 2025, reporting revenues of $213 million, reflecting a 3% increase compared to the same period in the previous year. The medical segment contributed $154 million to the revenue, while the industrial segment accounted for $59 million, both showing a 3% year-over-year growth. The GAAP gross margin stood at 36%, with a GAAP operating margin of 10% and a non-GAAP operating margin of 12%. Net earnings were reported at $0.17 per diluted share, with non-GAAP net earnings at $0.26 per diluted share, an increase from $0.16 in the same quarter of fiscal year 2024. Cash flow from operations reached $17 million in the second quarter. The company ended the quarter with cash, cash equivalents, and marketable securities totaling $226 million, excluding $125 million of restricted cash related to the Senior Secured Note Add On. Despite the positive results, Varex indicated a short-term reduction in outlook due to high tariffs imposed by China on U.S. products, leading to paused purchases from several China-based customers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.